Last $1.74 USD
Change Today -0.47 / -21.27%
Volume 1.4M
TBIO On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

transgenomic inc (TBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $5.90
52 Week Low
12/12/14 - $1.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TRANSGENOMIC INC (TBIO)

Related News

No related news articles were found.

transgenomic inc (TBIO) Related Businessweek News

No Related Businessweek News Found

transgenomic inc (TBIO) Details

Transgenomic, Inc. operates as a biotechnology company that focuses advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States, Italy, the United Kingdom, Germany, France, and internationally. It operates in two segments, Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies. It employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple unknown mutations from virtually any sample type, including tissue biopsies, blood, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. The company sells its products through direct sales, support staff, dealers, and distributors to academic and medical institutions; and pharmaceutical, biotech, and commercial companies. Transgenomic, Inc. has a strategic collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.

165 Employees
Last Reported Date: 03/27/14
Founded in 1997

transgenomic inc (TBIO) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $87.5K
Compensation as of Fiscal Year 2013.

transgenomic inc (TBIO) Key Developments

Transgenomic, Inc. Announces Executive Changes

On February 12, 2015, the Board of Directors of Transgenomic Inc. appointed Robert Patzig as the standing Chairperson of the Board, effective immediately. Mr. Patzig has served as a member of the Board since 2010 and, prior to his appointment as standing Chairperson of the Board, was serving as interim Board Chairperson. Additionally, on February 12, 2015, the Board unanimously voted to appoint John Thompson as Chairperson of the Audit Committee of the Board, effective immediately. Mr. Thompson has served as a member of the Board since May 2014 and as a member of the Audit Committee of the Board since his appointment to the Board.

Transgenomic Announces Commercial Launch of its Multiplexed ICE COLD-PCRTM (MX-ICP) Product Line

Transgenomic Inc. announced that the commercial launch of its Multiplexed ICE COLD-PCRTM (MX-ICP) product line is scheduled in the first quarter of 2015. MX-ICP is an ultra-high sensitivity DNA amplification technology that allows the simultaneous detection of multiple mutations in multiple genes from either tumor or liquid samples, such as blood or urine, on all platforms. Multiplexed ICE COLD-PCR delivers major advantages compared to current sequencing technologies used on their own. It delivers at least a 100-fold improvement in sensitivity, detecting previously unknown genetic alterations along with those that are already known. Its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies, by accurately analyzing cell-free tumor DNA circulating in the blood or other bodily fluids. Importantly, MX-ICP is platform agnostic, it works on all the sequencing platforms found in labs, greatly enhancing the sensitivity of next-generation sequencing, Digital PCR, Sanger, and other platforms. MX-ICP is easy to use, is highly reliable and is easily implemented, requiring minimal disruption to current sequencing processes or procedures.

Transgenomic, Inc. Announces Resignation of Rodney S. Markin from the Board of Directors, Effective from December 31, 2014

On December 18, 2014, Rodney S. Markin, M.D., Ph.D. notified Transgenomic Inc. of his decision to resign from the board of directors of the company, including from his position as chairman of the board, and from all committee memberships, effective as of December 31, 2014. Dr. Markin's decision to resign from the board was for personal reasons and was not due to any disagreement with the company on any matter relating to the company's operations, policies or practices.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBIO:US $1.74 USD -0.47

TBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Illumina Inc $195.46 USD -3.00
Laboratory Corp of America Holdings $123.03 USD -1.48
QIAGEN NV €22.50 EUR +0.32
Quest Diagnostics Inc $70.14 USD -0.96
Sequenom Inc $3.50 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation TBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENOMIC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at